CRISPR-Cas13 Precision Transcriptome Engineering in Cancer

Area of Science:

• Molecular Biology
• Genetics
• Biotechnology

Background:

• The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated genes (Cas) system is widely used for genomic engineering.
• A novel RNA-targeting CRISPR effector, Cas13, has been identified, functioning similarly to eukaryotic RNA interference.
• Cas13 effectors (Cas13a-Cas13d) efficiently cleave single-stranded RNAs, offering a safer alternative to DNA-targeting Cas9.

Purpose of the Study:

• To explore the potential of CRISPR-based RNA-targeting approaches for interrogating gene function in cancer.
• To highlight the applications of Cas13 in transcriptome engineering, base editing, and nucleic acid detection for cancer diagnostics and therapeutics.

Main Methods:

• Utilizing Cas13 effector proteins for RNA cleavage and transcriptome manipulation.
• Employing the REPAIR system for precise base editing of RNA transcripts.
• Leveraging advanced Cas13 engineering for nucleic acid detection platforms like Specific High Sensitivity Enzymatic Reporter Unlocking.

Main Results:

• Cas13 enables loss-of-function phenotypes without altering the genome, providing a safer gene editing strategy.
• The REPAIR system allows for editing of full-length transcripts, correcting pathogenic mutations.
• Cas13-based platforms facilitate mutation detection in cell-free tumor DNA.

Conclusions:

• CRISPR-based RNA-targeting offers a powerful toolkit for precise transcriptome engineering.
• These advancements hold significant potential for developing novel cancer therapeutics and diagnostics.
• Further exploration of CRISPR-based RNA targeting is crucial for interrogating cancer gene function.